| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Provision for income taxes | 0 | 0 | - | - |
| Revenue | 513,792 | 496,353 | 436,378 | 390,852 |
| Cost of goods sold | 61,860 | 81,082 | 77,844 | 36,796 |
| Gross profit | 451,932 | 415,271 | 358,534 | 354,056 |
| Research and development | 0 | 4,201 | 5,762 | 6,425 |
| Depreciation and amortization | 14,880 | 14,881 | 14,880 | 14,880 |
| Selling, general and administrative | 404,967 | 345,043 | 350,698 | 367,886 |
| Total operating expenses | 419,847 | 364,125 | 371,340 | 389,191 |
| Operating income (loss) | 32,085 | 51,146 | -12,806 | -35,135 |
| Other income | 0 | 0 | - | 1,458 |
| Interest expense-Related Party | 12,571 | 12,572 | - | - |
| Interest expense-Nonrelated Party | - | 12,862 | - | - |
| Interest expense, nonoperating | - | - | - | 12,571 |
| Loss on foreign currency exchange | -640 | 1 | - | -103 |
| Total other income (expense) | -27,095 | -25,433 | -25,708 | -24,635 |
| Income (loss) before provision for income taxes | 4,990 | 25,713 | -38,514 | -59,770 |
| Net income (loss) from continuing operations | 4,990 | 25,713 | -38,514 | -59,770 |
| Loss from discontinued operations, net of tax | -54 | -1,826 | -49 | -47 |
| Net income (loss) | 4,936 | 23,887 | -38,563 | -59,817 |
| Preferred stock dividends | 162,185 | 0 | 162,185 | 162,185 |
| Net loss available to common stockholders | -157,249 | 23,887 | -200,748 | -222,002 |
| Income loss available to common stockholders - basic | 0 | 0 | -0.01 | -0.01 |
| Income loss available to common stockholders - diluted | 0 | 0 | -0.01 | -0.01 |
| Weighted average number of shares outstanding - basic | 33,372,796 | 33,372,796 | 33,372,796 | 32,903,493 |
| Weighted average number of shares outstanding -diluted | 33,372,796 | 38,667,862 | 33,372,796 | - |
VYCOR MEDICAL INC (VYCO)
VYCOR MEDICAL INC (VYCO)